Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients

References

• JemalABrayFCenterMMFerlayjWardEFormanDGlobal cancer statisticsCA Cancer J Clin201161699021296855
   PubMed Web of Science ®Google Scholar
• StearnsVRaeJMPharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Expert Rev Mol Med2008e3410.1017/S146239940800089619019258
   PubMedGoogle Scholar
• BrauchHMürdterTEichelbaumMSchwabMPharmacogenomics of tamoxifen therapyClin Chem2009551770178219574470
   PubMed Web of Science ®Google Scholar
• BriestSStearnsVTamoxifen metabolism and its effect on endocrine treatment of breast cancerClin Adv Hematol Oncol20097318519219398943
   PubMedGoogle Scholar
• IngelJNPharmacogenetics and pharmacogenomics of endocrine agents for breast cancerBreast Cancer Res200810Suppl 4S4S719128442
   PubMed Web of Science ®Google Scholar
• IngelJNPharmacogenomics of tamoxifen and aromatase inhibitorsCancer2007112S3695699
   Web of Science ®Google Scholar
• HoskinsJMCareyLAMcLeodHLCYP2D6 and tamoxifen: DNA matters in breast cancerNat Rev Cancer2009957658619629072
   PubMed Web of Science ®Google Scholar
• BeverageJNSissungTMSionAMDanesiRFiggWDCYP2D6 polymorphisms and the impact on tamoxifen therapyJ Pharm Sci20079692224223117518364
   PubMed Web of Science ®Google Scholar
• HigginsMJStearnsVCYP2D6 Polymorphisms and tamoxifen metabolism: Clinical relevanceCurr Oncol Rep20101271520425602
   PubMed Web of Science ®Google Scholar
• GoetzMPKamalAAmesMMTamoxifen pharmacogenomis: the role of CYP2D6 as a predictor of drug responseClin Pharmacol Ther200883116016617882159
   PubMed Web of Science ®Google Scholar
• KuroseKSugiyamaESaitoYPopulation differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: Implications in the clinical trials for the novel drug developmentDrug Metab Pharmacokinet201227195422123129
   PubMed Web of Science ®Google Scholar
• BernardSNevilleKANguyenATFlockhartDAInterethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implicationsOncologist20061112613516476833
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J2005561315492763
   PubMed Web of Science ®Google Scholar
• BennyKAdithnanACGenetic polymorphisms of CYP2D6Indian J Pharmacol200133147169
   Google Scholar
• AbrahamJEMaranianMJDriverKECYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients for the United Kingdom treated with adjuvant tamoxifenBreast Cancer Res2008124R6420731819
   PubMed Web of Science ®Google Scholar
• SchrothWGoetzMPHamannUAssociation between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenJAMA2009302131429143619809024
   PubMed Web of Science ®Google Scholar
• CajalTRAltésAParéLImpact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatmentBreast Cancer Res Treat20101191333819189210
   PubMed Web of Science ®Google Scholar
• BorgesSDestaZLiLQuantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatmentClin Pharmacol Ther2006801617416815318
   PubMed Web of Science ®Google Scholar
• Blevins-PrimeauASSunDChenGFunctional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolitesCancer Res20096951892190019244109
   PubMed Web of Science ®Google Scholar
• GuillemetteCPharmacogenomics of human UDP-gluconosyltransferase enzymesPharmacogenomics J2003313615812815363
   PubMed Web of Science ®Google Scholar
• LinGFGuoWCChenJGAn association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in ChinaToxicol Sci200585150250615615884
   PubMed Web of Science ®Google Scholar
• NakmahachalasintPGenetic polymorphisms and CYP2D6 activity in Thai subjects [master’s thesis]Faculty of Pharmaceutical SciencesChulalongkorn University2003
   Google Scholar
• PechatananKJaruhathaiSAtivitavasTCytochrome P4502D6 polymorphisms of Thai patients with breast cancer and their outcomes of adjuvant tamoxifenJ Clin Oncol201129Supple11037
   Web of Science ®Google Scholar
• SukasemCSirachainanEChamnanphonMImpact of CYP2D6 polymorphisms on tamoxifen Responses of woman with breast cancer: a microarray-based study in ThailandAsian Pacific J Cancer Prev201213945494553
   Google Scholar
• ZhuYBZhangQZouJJOptimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical studyJ Pharm Biomed Anal200822462349355
   Web of Science ®Google Scholar
• SirachainanEJaruhathaiSTrachuNCYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patientsPharmacogenomics Pers Med20125149153
   PubMedGoogle Scholar
• JinYDestaZStearnsVCYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentJ Natl Cancer Inst2005971303915632378
   PubMed Web of Science ®Google Scholar
• MadlenskyLNatarajanLTchuSTamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomesClin Pharmacol Ther201189571872521430657
   PubMed Web of Science ®Google Scholar
• KiyatoniKMushirodaTImamuraCKDose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patientsBreast Cancer Res Treat201113113714521947681
   PubMed Web of Science ®Google Scholar
• AhernTPChristensenMCronin-FentonDPFunctional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivorsCancer Epidemiol Biomarkers Prev20112091937194321750172
   PubMed Web of Science ®Google Scholar
• RaeJMDrurySHayesDFCYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJ Natl Cancer Inst201221104645246022395643
   PubMedGoogle Scholar
• MűrdterTESchrothWBacchus-GerybadzeActivity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaClin Pharmocol Ther2011895708717
   PubMed Web of Science ®Google Scholar